targeted drugstoxicitiesTreatment of cancer has shifted dramatically over the past 2 decades. Targeted agents are used to block pathways known to drive tumor growth. Immunotherapy agents work by reversing cancer's ability to evade immune checkpoints, resulting in effective immune responses. With these...
Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours. This achievement, to be reported at the ESMO 2018 Congress in Munich,(1) shows tha...
Despite the encouraging preclinical and clinical data that is emerging on the use of ADCs for cancer therapy, a number of challenges remain for the successful clinical translation of these drugs, some of which might represent inherent limitations in the use of antibodies as drug carriers. The most...
Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours. This achievement, to be reported at the ESMO 2018 Congress in Munich, shows that cutting-edge precision ...
One way to maximize the effect and minimize the side effects of cancer therapeutics is the targeting of drugs to the tumor by using the specificity of antibodies. All different kinds of drug have been targeted to the tumor by this approach. In this review the targeting of chemotherapeutics, to...
This means NHS England will continue to fund the drug for this group of patients indefinitely, rather than for the time-limited period specified under the Cancer Drugs Fund. "NICE's recommendation that NHS England should also continue to fundosimertinibas a second-line treatment for some patients...
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy ArticleOpen access27 November 2023 Introduction Cancer remains a leading cause of death worldwide, posing a significant burden on global health.1,2The high incidence of cancer may be caused by ...
Targeted drug conjugate systems have emerged as a promising therapeutic strategy for the treatment of ovarian cancer. These systems provide the opportunity to selectively deliver highly potent chemotherapeutic drugs to ovarian cancer, sparing healthy normal cells. Thus, the effectiveness of the drugs is ...
Gastric cancer represents one of the most common cancers internationally. Unfortunately the majority of patients still present at an advanced stage, and de
This finding provides a novel justification for the precise treatment of patients exhibiting low HER2 expression, thereby compelling the use of FDA-approved T-DXd for the treatment of patients with low HER2 expression in breast cancer. As of 2021, there are curruntly 34 ADC drugs in clinical ...